switch to tirzepatide from semaglutide Switching Switching from Semaglutide to Tirzepatide:

Storage and handling: protecting your doses Correct dosing means nothing if the medication in your vial has degraded

Following subcutaneous administration in clinical models: Both components demonstrate prolonged absorption with peak plasma concentrations occurring 24-72 hours post-injection GLP3 exhibits approximately 6-day half-life enabling once-weekly dosing Cagrilintide demonstrates 120-165 hour half-life (5-7 days) suitable for weekly administration Lipid conjugation of both peptides enables albumin binding and extended systemic circulation Distribution patterns show systemic exposure with concentration in metabolically active tissues The fatty diacid modifications on both peptides (C20 for GLP3 , eicosanedioic acid for cagrilintide) serve as albumin-binding moieties that dramatically extend plasma residence time compared to native peptides

Persistent abdominal swelling, an inability to pass stools or gas, or severe pain needs urgent medical review

It also reduces gastric emptying, providing a feeling of fullness, and lowers the desire for food intake by making you feel satiated

Moreover, though it appears to improve blood sugar and insulin levels, its not a substitute for diabetes medication